Kelly King

The IGNYTE trial reveals that RP1 combined with nivolumab offers significant, durable responses in advanced melanoma patients previously resistant to anti-PD-1 therapy.

Biomarker testing in non–small cell lung cancer evolves with new protein-based markers and AI, enhancing personalized treatment strategies for patients.

The FDA prioritizes Orca-T's review for treating hematologic malignancies, promising improved survival and reduced complications compared with traditional therapies.